- Home
- EUDA vs MGNX Comparison
EUDA vs MGNX Comparison
Compare EUDA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EUDA
- MGNX
- Stock Information
- Founded
- EUDA 2021
- MGNX 2000
- Country
- EUDA Singapore
- MGNX United States
- Employees
- EUDA N/A
- MGNX N/A
- Industry
- EUDA Blank Checks
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- EUDA Finance
- MGNX Health Care
- Exchange
- EUDA Nasdaq
- MGNX Nasdaq
- Market Cap
- EUDA 139.3M
- MGNX 125.2M
- IPO Year
- EUDA N/A
- MGNX 2013
- Fundamental
- Price
- EUDA $3.71
- MGNX $1.22
- Analyst Decision
- EUDA
- MGNX Hold
- Analyst Count
- EUDA 0
- MGNX 10
- Target Price
- EUDA N/A
- MGNX $6.83
- AVG Volume (30 Days)
- EUDA 105.8K
- MGNX 764.1K
- Earning Date
- EUDA 01-01-0001
- MGNX 05-08-2025
- Dividend Yield
- EUDA N/A
- MGNX N/A
- EPS Growth
- EUDA N/A
- MGNX N/A
- EPS
- EUDA N/A
- MGNX N/A
- Revenue
- EUDA $3,811,496.00
- MGNX $149,962,000.00
- Revenue This Year
- EUDA $66.63
- MGNX N/A
- Revenue Next Year
- EUDA $119.95
- MGNX $25.32
- P/E Ratio
- EUDA N/A
- MGNX N/A
- Revenue Growth
- EUDA N/A
- MGNX 155.26
- 52 Week Low
- EUDA $1.64
- MGNX $1.17
- 52 Week High
- EUDA $6.30
- MGNX $19.54
- Technical
- Relative Strength Index (RSI)
- EUDA 44.94
- MGNX 18.97
- Support Level
- EUDA $3.59
- MGNX $1.89
- Resistance Level
- EUDA $4.04
- MGNX $2.24
- Average True Range (ATR)
- EUDA 0.21
- MGNX 0.16
- MACD
- EUDA -0.02
- MGNX -0.07
- Stochastic Oscillator
- EUDA 18.75
- MGNX 4.55
About EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem aimed at making healthcare affordable and accessible, The company's proprietary unified AI platform quickly assesses a patient's medical history, triages a condition, digitally connects patients with clinicians, and predicts optimal treatment outcomes. The company caters to all stages of care, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and aftercare services. The company operates in two segments namely Medical services and property management services, out of which the company derives its maximum revenue from Medical services.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).